AR076265A1 - Derivados de indol para tratamiento antiviral - Google Patents

Derivados de indol para tratamiento antiviral

Info

Publication number
AR076265A1
AR076265A1 ARP100101146A ARP100101146A AR076265A1 AR 076265 A1 AR076265 A1 AR 076265A1 AR P100101146 A ARP100101146 A AR P100101146A AR P100101146 A ARP100101146 A AR P100101146A AR 076265 A1 AR076265 A1 AR 076265A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
amino
heteroaryl
aryl
Prior art date
Application number
ARP100101146A
Other languages
English (en)
Original Assignee
Schering Corp
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Ptc Therapeutics Inc filed Critical Schering Corp
Publication of AR076265A1 publication Critical patent/AR076265A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Compuestos y composiciones farmacéuticas de utilidad para tratar una infeccion viral o para afectar la actividad viral al modular la replicacion viral util para hepatitis AyC, HIV, herpes. Reivindicacion 1: Un compuesto de la formula (1): o uno de sus ácidos libres, bases libres, sales, hidratos, solvatos, clatratos, isotopologos, racematos, enantiomeros, diastereomeros, estereoisomeros o sus formas polimorficas, en donde X es hidrogeno, halogeno, ciano, nitro, carboxilo, alquil C1-8-carbonilo, alcoxi C1-8-carbonilo, formilo, amino, alquil C1-8-amino, aminocarbonilo, alquil C1-8-amino-carbonilo o alquil C1-8-sulfonilo; Ar es heteroarilo o heterociclilo, cada uno opcionalmente sustituido con uno o dos sustituyentes seleccionados, de modo independiente, de halogeno, alquilo C1-8, halo-alquilo C1-8, alcoxi C1-8, halo-alcoxi C1-8, amino o alquil C1-8-amino; Z es alquilo C1-8, alquenil C2-8-alquilo C1-8, alquinil C2-8-alquilo C1-8, halo-alquilo C1-8, alcoxi C1-8-alquilo C1-8, alcoxi C1-8-carbonilo, carboxilo, cicloalquilo C3-14, cicloalquenilo C3-14, cicloalquil C3-14-alquilo C1-8, arilo, aril-alquilo C1-8, heteroarilo, heteroaril-alquilo C1-8, heterociclilo o heterociclil-alquilo C1-8, en donde cada instancia de arilo y heteroarilo está opcionalmente sustituido con uno, dos, tres o cuatro sustituyentes seleccionados cada uno de hidroxi, chano, nitro, halogeno, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, hidroxi-alquilo C1-8, halo-alquilo C1-8, alcoxi C1-8, halo-alcoxi C1-8, amino, alquil C1-8-amino, alcoxi C1-8-alquilo C1-8, alquil C1-8-tio, alquil C1-8-carbonilo, alcoxi C1-8-carbonilo, alquil C1-8-carboniloxi o amino-sulfonilo; R1 es -N(R3)-SO2-R4, -N(R3)-SO2-N(R5)-R6, -SO-N(R5)-R6 o -SO2-R7; R2 es uno, dos, tres o cuatro sustituyentes seleccionados cada uno de hidrogeno, halogeno, hidroxi, ciano, nitro, alquilo C1-8, hidroxi-alquilo C1, halo-alquilo C1-8, alquenilo C2-8, halo-alquenilo C2-8, alcoxi C1-8, halo-alcoxi C1-8, alcoxi C1-8-alquilo C1-8, alquil C1-8-carbonilo, alcoxi C1-8-carbonilo, alquil C1-8-carboniloxi, alquil C1-8-carboniloxi-alquilo C1-8, alquil C1-8-carboniloxi-alcoxi C1-8, amino, alquil C1-8-amino, amino-alquilo C1-8, alquil C1-8-amino-alquilo C1-8, amino- alcoxi C1-8, alquil C1-8-amino-alcoxi C1-8, alcoxi C1-8-alquil C1-8-amino-alcoxi C1-8, amino-alquil C1-8-amino-alcoxi C1-8, alquil C1-8-amino-alquil C1-8-amino-alcoxi C1-8, alcoxi C1-8-carbonil-amino, carboxil-amino, amino-carbonilo, amino-carbonil-amino, alquil C1-8-amino-carbonil-amino, alquil C1-8-tio, alquil C1-8-sulfinilo, alquil C1-8-sulfonilo, alquil C1-8-sulfonil-amino, cicloalquilo C3-14, cicloalquil C3-14-alquilo C1-8, cicloalquil C3-14-alcoxi C1-8, cicloalquil C3-14-oxi, arilo, aril-alquilo C1-8, aril-alcoxi C1-8, ariloxi, aril-carbonil-amino, heteroarilo, heteroaril-alquilo C1-8, heteroaril-alcoxi C1-8, heteroariloxi, heterociclilo, heterociclil-alquilo C1-8, heterociclil-alcoxi C1-8, heterocicliloxi o heterociclil-carboniloxi, en donde cada instancia de arilo, heteroarilo y heterociclilo está opcionalmente sustituido con uno, dos, tres o cuatro sustituyentes seleccionados cada uno de halogeno, ciano, alquilo C1-8, alcoxi C1-8, alcoxi C1-8-alquilo C1-8, amino, alquil C1-8-amino, amino-alquilo C1-8 o alquil C1- 8-amino-alquilo C1-8; R3 es hidrogeno o alquilo C1-8, opcionalmente sustituido en el alquilo C1-8 con uno o varios sustituyentes seleccionados cada uno de halogeno, hidroxi, ciano, alcoxi C1-8, amino o alquil C1-8-amino; R4 es alquilo C1-8, halo-alquilo C1-8, alcoxi C1-8, halo-alcoxi C1-8, cicloalquilo C3-14, cicloalquil C3-14-alquilo C1-8, arilo, aril-alquilo C1-8, heteroarilo, heteroaril-alquilo C1-8, heterociclilo o heterociclil-alquilo C1-8, en donde cada instancia de arilo, heteroarilo, heterociclilo y cicloalquilo C3-14 está opcionalmente sustituido con uno o dos sustituyentes seleccionados cada uno de halogeno, alquilo C1-8, halo-alquilo C1-8, alcoxi C1-8, halo-alcoxi C1-8, amino o alquil C1-8-amino; R5 es hidrogeno, alquilo C1-8, alquil C1-8-carbonil- o cicloalquilo C3-14, opcionalmente sustituido en el alquilo C1-8 con uno o varios sustituyentes seleccionados cada uno de halogeno, hidroxi, ciano o alcoxi C1-8; R6 es hidrogeno, alquilo C1-8, hidroxi-alquilo C1-8, halo-alquilo C1-8, ciano-alquilo C1-8, alcoxi C1-8-alquilo C1-8, amino-alquilo C1-8, alquil C1-8-amino-alquilo C1-8, alquil C1-8-carbonilo, alcoxi C1-8-carbonilo, cicloalquilo C3-14, cicloalquil C3-14-alquilo C1-8, arilo, aril-alquilo C1-8, heteroarilo, heteroaril-alquilo C1-8, heterociclilo o heterociclil-alquilo C1-8, en donde cada instancia de arilo, heteroarilo, heterociclilo y cicloalquilo C3-14 está opcionalmente sustituido con uno o dos sustituyentes seleccionados cada uno de halogeno, alquilo C1-8, halo-alquilo C1-8, alcoxi C1-8, halo-alcoxi C1-8, amino o alquil C1-8-amino; y R7 es alquilo C1-8, cicloalquilo C3-14, cicloalquil C3-14-alquilo C1-8, arilo, aril-alquilo C1-8, heteroarilo, heteroaril-alquilo C1-8, heterociclilo o heterociclil-alquilo C1-8, en donde cada instancia de arilo, heteroarilo, cicloalquilo C3-14 y heterociclilo está opcionalmente sustituido con uno o dos sustituyentes seleccionados cada uno de halogeno, alquilo C1-8, halo-alquilo C1-8, alcoxi C1-8, halo-alcoxi C1-8 amino o alquil C1-8-amino.
ARP100101146A 2009-04-06 2010-04-06 Derivados de indol para tratamiento antiviral AR076265A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16689309P 2009-04-06 2009-04-06

Publications (1)

Publication Number Publication Date
AR076265A1 true AR076265A1 (es) 2011-06-01

Family

ID=42257856

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101146A AR076265A1 (es) 2009-04-06 2010-04-06 Derivados de indol para tratamiento antiviral

Country Status (21)

Country Link
US (1) US8735414B2 (es)
EP (1) EP2417122A1 (es)
JP (1) JP2012522806A (es)
KR (1) KR20120007026A (es)
CN (1) CN102695704A (es)
AR (1) AR076265A1 (es)
AU (1) AU2010234650A1 (es)
BR (1) BRPI1010514A2 (es)
CA (1) CA2757640A1 (es)
CO (1) CO6450616A2 (es)
CR (1) CR20110542A (es)
EC (1) ECSP11011434A (es)
IL (1) IL215559A0 (es)
MX (1) MX2011010482A (es)
NI (1) NI201100178A (es)
NZ (1) NZ596144A (es)
RU (1) RU2011144819A (es)
SG (2) SG175047A1 (es)
TW (1) TWI427076B (es)
WO (1) WO2010117932A1 (es)
ZA (1) ZA201108107B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2880178C (en) * 2012-07-27 2021-10-26 Sato Pharmaceutical Co., Ltd. Difluoromethylene compound
US10721929B2 (en) * 2016-09-16 2020-07-28 Sumitomo Chemical Company, Limited Heterocyclic compound and harmful-arthropod-controlling agent containing same
WO2018213365A1 (en) * 2017-05-15 2018-11-22 Dana-Farber Cancer Institute, Inc. Compounds for treating dengue virus infection and other viral infections
DK3860998T3 (da) 2018-10-05 2024-03-25 Annapurna Bio Inc Forbindelser og sammensætninger til behandlinger af tilstande, der er forbundet med APJ-receptoraktivitet
CN113135900B (zh) * 2021-03-12 2022-05-24 中山大学 吲哚嘧啶类化合物及其合成方法和应用
CN112891343B (zh) * 2021-03-22 2022-04-01 华中农业大学 3-吲哚乙腈在制备抑制新型冠状病毒SARS-CoV-2药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200103147T1 (tr) * 1999-12-27 2002-06-21 Japan Tobacco Inc. Kaynaşık halkalı bileşikler ve bunların ilaç olarak kullanımı.
US7223785B2 (en) * 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CN1798726A (zh) * 2003-06-05 2006-07-05 麦克公司 取代吲哚及一种制备取代吲哚的方法
US20050119318A1 (en) * 2003-10-31 2005-06-02 Hudyma Thomas W. Inhibitors of HCV replication
US8013006B2 (en) * 2004-07-14 2011-09-06 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) * 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US20060235028A1 (en) 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
WO2007027454A1 (en) * 2005-08-30 2007-03-08 Bristol-Myers Squibb Company Heterocyclic dihydropyrimidine compounds
WO2008009079A2 (en) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
PE20090223A1 (es) * 2007-05-04 2009-03-08 Wyeth Corp Compuestos triciclicos como inhibidores de metaloproteinasas matriciales
AR072297A1 (es) * 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
CA2755968C (en) * 2008-10-06 2019-03-19 Andrey Alexandrovich Ivashchenko Substituted 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines, serotonin 5-ht6 receptor antagonists and methods for the production and use thereof

Also Published As

Publication number Publication date
SG175048A1 (en) 2011-11-28
BRPI1010514A2 (pt) 2019-09-24
RU2011144819A (ru) 2013-05-20
ZA201108107B (en) 2013-01-30
KR20120007026A (ko) 2012-01-19
IL215559A0 (en) 2011-12-29
TWI427076B (zh) 2014-02-21
CO6450616A2 (es) 2012-05-31
US8735414B2 (en) 2014-05-27
JP2012522806A (ja) 2012-09-27
CN102695704A (zh) 2012-09-26
AU2010234650A1 (en) 2011-11-03
ECSP11011434A (es) 2011-12-30
MX2011010482A (es) 2012-01-30
SG175047A1 (en) 2011-11-28
EP2417122A1 (en) 2012-02-15
NI201100178A (es) 2012-01-23
NZ596144A (en) 2014-01-31
CA2757640A1 (en) 2010-10-14
US20120184574A1 (en) 2012-07-19
CR20110542A (es) 2012-01-30
WO2010117932A1 (en) 2010-10-14
TW201103900A (en) 2011-02-01

Similar Documents

Publication Publication Date Title
AR076265A1 (es) Derivados de indol para tratamiento antiviral
PE20230376A1 (es) Compuestos moduladores de la diacilglicerol quinasa
AR076266A1 (es) Compuestos de azaindol, composiciones farmaceuticas y uso de los compuestos en el tratamiento de hcv
CR20190504A (es) COMPUESTO DE AMIDA (Divisional 2015-0454)
ECSP16016726A (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
PE20171306A1 (es) Derivados de quinazolina utilizados para tratar el vih
AR101600A1 (es) COMPUESTOS DE SPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2-p53
DOP2019000140A (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
BR112018013251A2 (pt) compostos heterocílicos tricíclicos fundidos como inibidores da hiv integrase
CO6220878A2 (es) Composicion herbicida que comprende un derivado de isoxazolina o una sal del mismo
PE20121526A1 (es) Compuestos policiclicos heterociclicos como inhibidores del virus de la hepatitis c
AR101788A1 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
AR085354A1 (es) Derivados de isoxazol para control de pestes invertebrados
AR068639A1 (es) Derivados de biarilo
AR062366A1 (es) Derivados de pirazoles como inhibidores no nucleosidicos de la transcriptasa inversa, composiciones farmaceuticas
NI201200146A (es) Inhibidores no nucleosídicos de la transcriptasa inversa
EA201170537A1 (ru) Ингибиторы вич-интегразы
AR073659A1 (es) Compuetsos inhibidores de la hepatitis c
AR053345A1 (es) Compuesto de 1,2,4 triazolo-5-ona como inhibidores de la transcriptasa inversa
AR062827A1 (es) Inhibidores virales policiclicos, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de una infeccion viral mediada porl el virus de la hepatitis c
CO2022003123A2 (es) Compuestos farmacéuticos
AR076268A1 (es) Combinaciones de inhibidor de vhc y agentes terapeuticos. metodo. uso.
CO2021004873A2 (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
UY38934A (es) Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica
BR112018000253A2 (pt) composto, composição, e, método para tratar a infecção pelo hiv.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal